Method for improving production of streptomyces polyketide compounds
US-2023056311-A1 · Feb 23, 2023 · US
Recombinant microorganism expressing avermectin analogue and use thereof
US10334850B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10334850-B2 |
| Application number | US-201415123827-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 28, 2014 |
| Priority date | Mar 10, 2014 |
| Publication date | Jul 2, 2019 |
| Grant date | Jul 2, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a recombinant microorganism expressing avermectin or analogs thereof and construction method thereof, and also relates to a method of producing avermectin or analogs thereof using the recombinant microorganism, and avermectin or analogs thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogs thereof as insecticides. Using the recombinant microorganism of the present invention to produce avermectin or analogs thereof has numerous advantages, for example comprising at least one of the following: good stability, high yield, simple process, environmentally friendly, and greatly saving of production costs.
First claim
Opening claim text (preview).
The invention claimed is: 1. A recombinant Streptomyces expressing tenvermectin A or tenvermectin B, wherein the recombinant Streptomyces (1) has an inactivated or activity-decreased aveD gene, has an inactivated or activity-decreased aveAI gene, and has a functional milAI gene; or (2) has an inactivated or activity-decreased aveAI gene, and has a functional milAI gene. 2. The recombinant Streptomyces according to claim 1 , wherein the recombinant Streptomyces is Streptomyces avermitilis. 3. A method for producing tenvermectin A or tenvermectin B, the method comprising: culturing the recombinant Streptomyces of claim 1 , and recovering tenvermectin A or tenvermectin B from the culture. 4. A method for constructing the recombinant Streptomyces of claim 1 , said method comprising: providing a Streptomyces to be modified; and inactivating the aveAI gene in the Streptomyces to be modified or decreasing the activity thereof, and introducing the functional milAI gene into the Streptomyces to be modified. 5. The method according to claim 4 , wherein the Streptomyces to be modified is Streptomyces avermitilis.
Assignees
Inventors
Classifications
- C12P19/623Primary
Avermectin; Milbemycin; Ivermectin; C-076 · CPC title
for Actinomyces; for Streptomyces · CPC title
- A01N43/90Primary
having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system · CPC title
Chemistry & Metallurgy · mapped topic
Streptomyces · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10334850B2 cover?
- The present invention relates to a recombinant microorganism expressing avermectin or analogs thereof and construction method thereof, and also relates to a method of producing avermectin or analogs thereof using the recombinant microorganism, and avermectin or analogs thereof obtained using the method. In addition, the present invention further relates to uses of the avermectin or analogs ther…
- Who is the assignee on this patent?
- Zhejiang Hisun Pharm Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12P19/623. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).